Pfizer Licenses Three Starna In Vivo CAR T Programs

Company Pfizer; Starna Therapeutics Event Type Exclusive license ($330 million upfront; up to $2.3 billion milestones) Modality In vivo CAR T via targeted LNP-delivered RNA Asset Three pre-IND autoimmune programs; platform rights Target Undisclosed Disease Area Autoimmune disease; inflammation, immunology and oncology platform rights Summary…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *